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Abstract
We investigated whether the application of the downgrade criteria to supplemental screening ultrasound (US) for women with
negative mammography but dense breasts can reduce the rate of Breast Imaging Reporting and Data System (BI-RADS) categories
3 to 4a without a loss of cancer detection.
This retrospective studywasapprovedby the InstitutionalReviewBoard, and the need toobtain informedconsentwaswaived. A total
of 3171consecutivewomen (978women, 1173women, and1020women in the ﬁrst, second, and third year, respectively)with negative
mammography but dense breast who underwent radiologist-performed, hand-held supplemental screening US from March 2010 to
February 2013were included. Downgrade criteria for BI-RADScategory 2were complicated cysts5mmobserved as circumscribed,
homogeneous, and hypoechoic lesions and circumscribed oval-shaped solid masses5mm. Changes in the distribution of BI-RADS
category, biopsy rate, and cancer detection yield over 3 years were analyzed. Performances of less-experienced (12 fellows with <2
years of experience) and experienced (3 staffs with >12 years of experience) radiologists were compared. Outcomes of initial
examinations (prevalence screening) and noninitial examinations (incidence screening) were compared.
Application of the downgrade criteria reduced BI-RADS categories 3 to 4a in both less-experienced (from 39.4% to 16.0%, P<0.001)
and experienced radiologists (from 22.6% to 11.1%,P<0.001) over 3 years. Biopsy rates also signiﬁcantly decreased from6.5% to 2.4%
(P<0.001).Cancer detection yield of supplemental screeningUSwas2.8per 1000examinations (9of 3171: 2ductal carcinoma in situ and
7 invasive cancers). Therewere no differences in cancer detection yield per each year (P=0.539). Therewas no interval cancer. In noninitial
examinations, BI-RADS categories 3 to 4a rates, biopsy rates, and cancer detection rates were lower compared to initial examinations.
Application of the downgrade criteria reduced BI-RADS categories 3 to 4a without a loss of cancer detection. We suggest that our
downgrade criteria can be used to reduce the false positive rate in the supplemental screening US. Further large-scale, multicenter,
prospective studies are needed to validate the effectiveness of the downgrade criteria.
Abbreviations: BI-RADS = Breast Imaging Reporting and Data System, BRCA = breast cancer susceptibility gene, DCIS =
ductal carcinoma in situ, HR= hormone receptor, HER2= human epidermal growth factor receptor 2, IHC= immunohistochemistry,
PPV = positive predictive value, US = ultrasound.
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11. Introduction
Mammography is the only screening modality that has been
proven to reduce mortality caused by breast cancer.[1] However,
the sensitivity of mammography decreases in dense breasts, and
invasive cancer is often mammographically subtle or occult when
the breast is dense.[2] These limitations have led to the introduction
of breast density notiﬁcation legislation in theUnited States and the
increasing demand for a supplemental screening tool.[3] Breast
ultrasound (US) is an attractive screening tool which is widely
available, well tolerated by patients, and without ionizing
radiation. Supplemental screening US in women with dense
breasts and/or the elevated risk of breast cancer has been shown to
detect additional cancers by an average of 4.2 cancers per 1000
women screened.[4–11] Most of the cancers identiﬁed by supple-
mental US are less than 1cm in size, invasive, and node-
negative.[4–6,8,9,11,12] However, screening US has resulted in a
high rate of positive test results (Breast Imaging Reporting and
Data System [BI-RADS] ﬁnal assessment categories 3–5).[4–8,13–15]
The average positive predictive value (PPV) for biopsies was only
9.5% with increased false positive biopsies which may be
associated with discomfort, emotional stress, and medical cost.[16]
In addition, operator dependence has long been a concern for
hand-held breast US when even performed by experienced
Kim et al. Medicine (2016) 95:44 Medicinephysicians, but few studies have evaluated the interoperator
variability of physician-performed hand-held US.[17,18]
In our 2009 results, radiologist-performed, hand-held supple-
mental screening US was shown to detect additional cancers (1.8
cancers per 1000 examinations [3 of 1656]) in women with
negative but dense breasts, but there were concerns regarding the
high rates of category 3 lesions (30.4%, 504 of 1656) compared
to mammography alone, and a low PPV of less than 3%.[9] Since
March 2010, to reduce the false positive rate, the downgrade
criteria which classify complicated cysts 5mm or smaller which
are observed as circumscribed, homogeneous, and hypoechoic
lesions 5mm or smaller and circumscribed oval-shaped solid
masses 5mm or smaller as category 2 were established and were
applied in our daily practice. These cysts and masses are often
seen on screening US, and according to BI-RADS, they are
assigned to category 3, probable benign ﬁnding, and then
undergo short-term follow-up examinations.[19] Some compli-
cated cysts may be assigned to category 4a, low-suspicious
ﬁnding. These cysts are then aspirated or biopsied, because they
can sometimes look like hypoechoic solid lesions with indistinct
or microlobulated margins and mild posterior shadowing, a
mimic of malignancy.[20] There may be a higher possibility of less-
experienced radiologists assigning them to category 4a. Howev-
er, a breast cancer presenting as a complicated cyst or
circumscribed oval-shaped solid mass 5mm or smaller is very
rare, with reported malignancy rates being less than 0.5%.[9,20,21]
Thus, we expected the categories 3 to 4a rate to be reduced
without a signiﬁcant loss of cancer detection, if the cysts or
masses are downgraded to category 2.
Therefore, the purpose of this study was to investigate whether
the application of the downgrade criteria to supplemental
screening US for women with negative mammography but dense
breasts can reduce BI-RADS categories 3 to 4a without a loss of
cancer detection.2. Methods
2.1. Study population
The study was approved by the Institutional Review Board, and
informed consent requirement was waived for this retrospective
study. From March 2010 to February 2013, 31,373 consecutive
women underwent mammograms in our institution. Using the
database of the radiology department, we searched for women
who met the following criteria. The inclusion criteria were as
follows: women who underwent screening mammography,
women who had dense breast deﬁned as BI-RADS density grade
3 (heterogeneously dense) or 4 (extremely dense) at mammogra-
phy,[19] women who had negative ﬁndings deﬁned as BI-RADS
ﬁnal assessment category 1 or 2 at mammography,[19] and
women who had radiologist-performed, hand-held supplemental
US examinations performed within 3 months after mammogra-
phy. The exclusion criteria were as follows: women who had
redundant US examinations which were performed twice or more
during a 1-year period due to early visits despite a BI-RADS
category 1 or 2 assessment on a prior examination, women with
known risk factors for breast cancer other than dense breast
(biopsy-proven lobular neoplasia or atypical ductal hyperplasia,
history of ovarian cancer, family history of breast cancer; there
was no case with chest irradiation history and breast cancer
susceptibility gene (BRCA) mutation was not considered because
BRCAmutation analysis had not been routinely performed at our
institution), andwomenwho did not undergo surgery nor follow-2up US examinations for at least 12 months. Finally, a total of
3171 women with negative mammography but dense breast who
underwent radiologist-performed, hand-held supplemental
screening US were included (mean age± standard deviation
[years], 51.2±7.7; range [years], 24–78): 978women (50.7±7.6;
27–75) in the ﬁrst year (from March 2010 to February 2011),
1173 women (50.9±7.6; 24–78) in the second year (fromMarch
2011 to February 2012), and 1020 women (52.0±7.9; 31–78) in
the third year (from March 2012 to February 2013). For each
year, the women were divided into 2 groups; women who
underwent initial US examinations at our institution (prevalence
screening) or who underwent previous US examinations at our
institution (incidence screening) to test the following hypothesis.
We hypothesized that the cancer detection rate, positive test rate,
and biopsy rate would be lower while PPV would be higher in
noninitial examinations compared to initial examinations for the
following reasons: in noninitial examinations, women with
cancer and/or positive tests at previous US examination had
already been excluded from the study population, and the degree
of attention or concentration of the radiologists performing US
may be lower for the noninitial examinations compared to initial
examinations.2.2. Screening mammography and US
Digital mammography was performed with a full-ﬁlled digital
mammography system (Lorad/Hologic Selenia, Lorad/Hologic,
Danbury, CT; SENOGRAPHE 2000D, GE Medical Systems,
Milwaukee, WI). Standard mediolateral oblique and craniocau-
dal views were routinely obtained. All mammograms were
interpreted by 1 of 15 breast radiologists (12 fellows with 1–2
years of experience [less-experienced group] and 3 faculties with
12–18 years of experience [experienced group]). The ﬁnal
assessment was prospectively determined according to BI-
RADS.[19] Radiologist-performed, hand-held bilateral whole-
breast US was performed by one of the aforementioned breast
radiologists with a 12- to 5-MHz linear array transducer (HDI
5000 or iU22, Phillips-Advanced Technology Laboratories,
Bothell, WA; Logic 9, GE Medical Systems, Milwaukee, WI).
At the radiologist’s discretion, color or power Doppler imaging
and harmonic imaging were performed. Elastography was not
performed. The radiologists were not blinded to mammography
and were able to review prior examinations and the clinical
information of patients. The ﬁnal assessment was prospectively
determined by the same radiologists who performed US
according to BI-RADS.[19] Since March 2010 (the starting year
of this study), in order to reduce the false positive rate, we have
trained our radiologists to classify the following ﬁndings as
category 2: a complicated cyst 5mm or smaller which were
observed as a circumscribed, homogeneous, and hypoechoic
lesion (Fig. 1A) and a circumscribed oval-shaped solid mass 5mm
or smaller without any suspicious US features (Fig. 1B). The 2
criteria for downgrading were selected in consensus after an in-
depth discussion between staff radiologists based on experience
and other publications.[9,20,21] During the study period, staff
radiologists continued to emphasize the downgrade criteria to
fellow radiologists at the weekly conference.
2.3. Follow-up
Short-interval follow-up US examinations were recommended
for category 3 lesions at 6, 12, and 24 months after category
3 assessments. If the lesion demonstrated stability during
Figure 1. A representative example of downgrade criteria: a complicated cyst 5mm or smaller (A) and a circumscribed oval-shaped solid mass 5mm or smaller (B).
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US-guided core needle biopsy using a 14-gauge automated core
biopsy needle (TSK Stericut biopsy needle, standard type with co-
axial, T SK Laboratory, Soja, Tochigi, Japan) was performed for
category 4 or 5 lesions immediately after US or for lesions with
increased size or newly developed suspicious lesions during
follow-up. Surgical excision was performed for biopsy results of
malignancy including ductal carcinoma in situ (DCIS) or invasive
cancer, and atypical or high-risk lesions including atypical ductal
hyperplasia, atypical lobular hyperplasia, papilloma, and
phyllodes tumor.[4] Immunohistochemistry (IHC) analysis for
receptors of breast cancers was performed.[22,23] Hormone
receptor (HR) positivity was deﬁned as estrogen receptor and/or
progesterone receptor positivity ≥1% nuclear staining. Human
epidermal growth factor receptor 2 (HER2) positivity was
deﬁned as having IHCHER2 score of 3+ or gene ampliﬁcation by
ﬂuorescence in situ hybridization in tumors with IHC HER2
score of 2+. Tumor subtypes were categorized based on the
receptor status asHR+ andHER2, HR+ andHER2+,HR and
HER2+, and HR and HER2 (triple negative).[24]2.4. Data and statistical analysis
The pathologic results of biopsy and surgery performed within 1
year of the screening US were reviewed. In patients with surgery,
surgical results showing malignancy were considered as disease
positive, and those showing benign results were considered as
disease negative. In patients without surgery, the absence of a
cancer diagnosis on follow-up US≥12 months after the initial US
was considered as disease negative. BI-RADS category 3 or higher
were considered as test positive and categories 1 and 2 were
considered as test negative.[14] Interval cancers were deﬁned asTable 1
Distribution of BI-RADS ﬁnal assessment category in supplemental s
Overall First year
Total examination
Categories 1–2 73.8 (2340/3171) 66.1 (646/978)
Categories 3–4a 25.9 (820/3171) 33.3 (326/978)
Initial examination
Categories 1–2 52.8 (527/998) 46.8 (185/395)
Categories 3–4a 46.3 (462/998) 51.9 (205/395)
Noninitial examination
Categories 1–2 83.4 (1813/2173) 79.1 (461/583)
Categories 3–4a 16.5 (358/2173) 20.8 (121/583)
Overall = from ﬁrst to third year. Total examination = initial plus noninitial examination. Values given are p
years using Mantel–Haenszel chi-square test.
3those diagnosed because of clinical abnormalities occurring in an
interval less than 1 year after the last screening US.
PPV1 was deﬁned as the malignancy rate among positive tests
(cancer/lesions with a BI-RADS 3 or higher).[19] PPV2 was
deﬁned as the malignancy rate among positive tests with biopsy
recommendations (cancer/BI-RADS 4 or 5 lesions).[19] PPV3 was
deﬁned as the malignancy rate of lesions with biopsy among BI-
RADS 4 or 5 lesions (cancers/lesions with biopsy among BI-
RADS 4 or 5 lesions).[19] The rates of BI-RADS category, PPVs,
and biopsy rates for trend over 3 years were evaluated using
Mantel–Haenszel chi-square test. The differences in total and
invasive cancer yields per year were evaluated using chi-square
or Fisher exact test. Differences in BI-RADS 3 to 4a rates, total,
and invasive cancer yields, PPVs, and biopsy rates were
compared between the 2 groups with initial or noninitial
examinations using chi-square test. The rates of BI-RADS 3 to
4a and total cancer yield were compared between less-
experienced and experienced radiologists using Mantel–-
Haenszel chi-square test for trend over 3 years and chi-square
or Fisher exact test for difference per year. P values of less than
0.05 were considered statistically signiﬁcant. All statistical
analyses were performed with SAS statistical software (version
9.2, SAS institute, Cary, NC).3. Results
With the application of the downgrade criteria, the rate of BI-
RADS categories 1 to 2 increased, and categories 3 to 4a
decreased over 3 years in total examinations, initial examina-
tions, and noninitial examinations (Table 1, all P<0.001). In
total examinations, BI-RADS categories 3 to 4a decreased from
33.3% to 14.6%. BI-RADS categories 3 to 4a were more presentcreening ultrasound.
Second year Third year P
70.2 (824/1173) 85.3 (870/1020) <0.001
29.4 (345/1173) 14.6 (149/1020) <0.001
51.2 (212/414) 68.8 (130/189) <0.001
47.8 (198/414) 31.2 (59/189) <0.001
80.6 (612/759) 89.0 (740/831) <0.001
19.4 (147/759) 10.8 (90/831) <0.001
ercentages (number of women with corresponding category/total women). P value for the trend over 3
Table 2
Total and invasive cancer yields of supplemental screening ultrasound.
Overall First year Second year Third year P
Total examination
Total cancer yield
‰ (95% CI) 2.8 (1.3–5.4) 2.0 (0.2–7.4) 4.3 (1.4–9.9) 2.0 (0.2–7.1) 0.539
No./total 9/3171 2/978 5/1173 2/1020
Invasive cancer yield
‰ (95% CI) 2.2 (0.9–4.5) 2.0 (0.2–7.1) 2.6 (0.5–7.5) 2.0 (0.2–7.1) >0.999
No./total 7/3171 2/978 3/1173 2/1020
Initial examination
Total cancer yield
‰ (95% CI) 4.0 (1.1–10.2) 2.5 (1.0–14.0) 7.3 (1.5–21.0) 0.0 (0.0–19.3) 0.535
No./total 4/998 1/395 3/414 0/189
Invasive cancer yield
‰ (95% CI) 4.0 (1.1–10.2) 2.5 (1.0–14.0) 7.3 (1.5–21.0) 0.0 (0.0–19.3) 0.535
No./total 4/998 1/395 3/414 0/189
Noninitial examination
Total cancer yield
‰ (95% CI) 2.3 (0.1–0.5) 1.7 (0.0–9.5) 2.6 (0.3–9.5) 2.4 (0.3–8.7) >0.999
No./total 5/2173 1/583 2/759 2/831
Invasive cancer yield
‰ (95% CI) 1.4 (0.3–4.0) 1.7 (0.0–9.5) 0.0 (0.0–4.8) 2.4 (0.3–8.7) 0.491
No./total 3/2173 1/583 0/759 2/831
Overall = from ﬁrst to third year. Total examination = initial plus noninitial examination. P value for difference per each year using chi-square or Fisher exact test. No./total = number of women with cancers/total
women, CI = conﬁdence interval.
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(46.3% [462 of 998] vs 16.5% [358 of 2173], P<0.001).3.1. Supplemental cancer detection yield
Screening US detected 9 additional cancers: 2 were DCIS and 7
were invasive cancers. Total cancer yield per 1000 examinations
was 2.8 (Table 2, 9 of 3171; 95% conﬁdence interval [CI],
1.3–5.4) and invasive cancer yield per 1000 examinations was
2.2 (7 of 3171; 95% CI, 0.9–4.5). There were no differences in
total and invasive cancer yields per year. Total cancer yield of
initial examinations was higher than that of noninitial exami-
nations without statistical signiﬁcance (4.0 [4 of 998] vs 2.3 [5 of
2173], P=0.475). Characteristics of the 9 US-detected cancers
are demonstrated in Table 3 and Figs. 2 and 3. The median size of
the 9 cancers was 8mm, ranging from 5 to 15mm. All had low or
intermediate histologic grades. IHC subtypes were either HR
positive/HER2 negative (77.8%, 7 of 9) or triple negative
(22.2%, 2 of 9). None had lymph node or distant metastasis.
There were no interval cancers.
3.2. PPV and biopsy rate
PPVs of total examinations showed an increasing trend over 3
years, although statistical signiﬁcance was not achieved (Table 4.
PPV1=0.6%, 1.4%, and 1.3% in ﬁrst, second, and third year,
respectively, P=0.494; PPV2 and PPV3=3.6%, 9.1%, and 9.5%
in ﬁrst, second, and third year, respectively, P=0.338). As all BI-
RADS 4 or 5 lesions underwent biopsy, PPV2 and PPV3 were the
same. Overall, PPVs of initial examinations were smaller than
those of noninitial examinations without statistical signiﬁcance
(PPV1, 0.9% vs 1.4%, P=0.512; PPV2 and PPV3, 4.5% vs
11.9%, P=0.145).
Overall, 147 lesions underwent US-guided 14-gauge core
needle biopsy. A total of 135 lesions (all BI-RADS 4 [n=132] and
5 lesions [n=1], and 2 lesions out of 700 BI-RADS 3 lesions due
to the request of the patient) immediately underwent biopsy. The4remaining 12 lesions underwent biopsy before a full year of
follow-up because of increased lesion size (n=5) or a newly
developed low-suspicious lesion (n=7) on follow-up US for BI-
RADS category 3. Overall, biopsy results consisted of 9 cancers
(2 DCIS and 7 invasive cancers), 6 high-risk lesions (4 atypical
ductal hyperplasia, 1 atypical papilloma, and 1 phyllodes tumor),
and 132 benign lesions. Surgery was performed for 9 cancers and
6 high-risk lesions, and 6 high-risk lesions were ﬁnally conﬁrmed
to be benign by surgery. Biopsy rates signiﬁcantly decreased over
3 years for total, initial, and noninitial examinations (Table 4).
The overall biopsy rate of initial examinations was signiﬁcantly
larger than that of noninitial examinations (9.6% vs 2.3%, P<
0.001).3.3. Comparison of the performance between less-
experienced and experienced radiologists
On the whole, the categories 3 to 4a rates were higher in less-
experienced compared to experienced radiologists (Table 5). The
categories 3 to 4a rates showed a decreasing trend over 3 years in
both groups. The gaps between the 2 groups for categories 3 to 4a
rates decreased over 3 years. There were no differences in total
cancer yields between the 2 groups. In both groups, categories 3
to 4a rates of initial examinations were signiﬁcantly higher than
those of noninitial examinations (all P<0.001).4. Discussion
The application of the downgrade criteria to supplemental
screening US reduced BI-RADS categories 3 to 4a in both less-
experienced and experienced radiologists over 3 years. Despite
the reduction of categories 3 to 4a, PPVs did not signiﬁcantly
increase, as the number of US-detected cancers was small. Our
total cancer yield of 2.8 cancers per 1000 examinations was
within the reported ranges of 0.3 to 6.8 cancers per 1000
examinations (median: 4.2),[4–11] and interval cancers were not
detected. Compared to our 2009 results which were found before
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Kim et al. Medicine (2016) 95:44 www.md-journal.com5the downgrade criteria was applied, the total cancer detection
yield of the present study was higher without statistical
signiﬁcance (1.8 cancers/1000 examinations in 2009[9] vs 2.8
cancers/1000 examinations in 2010–2012, P=0.559). These
results mean that the downgrade criteria effectively reduced BI-
RADS categories 3 to 4a without a loss of cancer detection—that
is, the false positive rates decreased.
We considered a complicated cyst 5mm or smaller which was
observed as a circumscribed, homogeneous, and hypoechoic
lesion as BI-RADS category 2. Complicated cysts are cysts with
internal debris.[25] When the debris is mobile or a ﬂuid-debris
level is seen, they are regarded as benign.[25] But, when the debris
is homogeneous and hypoechoic, it is often difﬁcult to distinguish
a complicated cyst from a solid mass, so they have been generally
classiﬁed as probable benign, BI-RADS category 3, or unneces-
sary aspiration or core needle biopsy has been occasionally
performed.[20,25,26] However, breast cancers presenting as
complicated cysts on US are very rare at percentages of less
than 0.5%, with a range of 0% to 0.4%.[6,20,26] A circumscribed
oval-shaped mass 5mm or smaller without any suspicious US
features was also considered as category 2. In previous studies,
there were no malignancies among masses less than 5mm
detected on screening US.[9,21] A Connecticut study by Hooley
et al and the ACRIN 6666 trial by Berg et al showed the similar
results compared to our study. The study by Hooley et al[6]
showed that the category 3 rate can decrease nearly 50% by
retrospectively classifying nonsimple cysts in the presence of
multiple cysts, and solitary, oval, circumscribed complicated
cysts 5mm or smaller as benign lesions without a loss of
sensitivity. The ACRIN 6666 trial had no malignancies among
multiple bilateral, similar-appearing circumscribed masses, and
had a very lowmalignancy rate (0.4%) for solitary circumscribed
masses (including complicated cyst, clustered microcyst, and
oval, round, or gently lobulated circumscribed solid mass).[26]
When we performed screening US with our downgrade criteria,
categories 3 to 4a rates were signiﬁcantly reduced, and there were
no interval cancers. Therefore, complicated cysts and circum-
scribed oval-shaped solid masses 5mm or smaller can be
downgraded to category 2, and a follow-up after 1 year is
suitable for these lesions.
One of the major problems of supplemental screening US is a
high rate of BI-RADS category 3.[6,15,26] In this study, the overall
category 3 rate during 3 years was 22.1%, signiﬁcantly lower
compared to 30.4% (504 of 1656) of our 2009 results (P<
0.001). The category 3 rate continuously decreased from 28.3%
to 12.6% over 3 years. Thus, the application of downgrade
criteria was effective in reducing the category 3 rate. The category
3 rate was 19.5% in the ACRIN 6666,[15] and 20% in the
Connecticut study,[6] similar to the 22.1%of our study. Although
the biopsy rate signiﬁcantly decreased over 3 years, 89.9% of the
lesions (132 of 147) had false positive biopsy results, which was
consistent with previously reported false positive biopsy
rates.[6,14,16]
Few studies have evaluated the interoperator variability of
physician-performed hand-held US.[17,18] Bosch et al[18] found
high interexamination agreement in both detection and classiﬁ-
cation across 3 radiologists with different experience levels; 1
resident and 2 senior investigators with each 3 and 5 years of
experience. Among 11 breast imaging radiologists with at least 3
years of experience (range, 3–26 years) who were trained and
qualiﬁed for ACRIN 6666, there was moderate agreement for
the BI-RADS ﬁnal assessment category.[17] In that study, a
comparison analysis according to the experience level of the
Figure 2. A 57-year-old woman with supplemental screening ultrasound (US)-detected breast cancer (ductal carcinoma in situ, low histologic grade, hormone
receptor positive/HER2 negative). Transverse (A) and longitudinal (B) gray-scale US images show a 6-mm-sized irregular hypoechoic solid mass with
microlobulated margins. It was assigned BI-RADS category 4a.
Figure 3. A 56-year-old woman with supplemental screening ultrasound (US)-detected breast cancer (invasive ductal carcinoma, intermediate histologic grade,
hormone receptor positive/HER2 negative). Transverse (A) and longitudinal (B) gray-scale US images show a 10-mm-sized irregular hypoechoic solid mass with
spiculated margin and posterior shadowing. It was assigned BI-RADS category 4c.
Table 4
PPV and biopsy rates of supplemental screening ultrasound.
Overall First year Second year Third year P
Total examination
PPV1
% (95% CI) 1.1 (0.5–2.1) 0.6 (0.1–2.2) 1.4 (0.5–3.3) 1.3 (0.2–4.7) 0.494
No./total 9/831 2/332 5/349 2/150
PPV2, PPV3
% (95% CI) 6.9 (3.2–12.6) 3.6 (0.4–12.5) 9.1 (3.0–20.0) 9.5 (1.2–30.4) 0.338
No./total 9/131 2/55 5/55 2/21
Biopsy rate
% (95% CI) 4.6 (4.1–6.8) 6.5 (4.9–8.3) 5.0 (3.8–6.8) 2.4 (1.4–3.5) <0.001
No./total 147/3171 64/978 59/1173 24/1020
Initial examination
PPV1
% (95% CI) 0.9 (0.2–2.2) 0.5 (0.0–2.6) 1.5 (0.3–4.3) 0.0 (0.0–6.1) >0.999
No./total 4/471 1/210 3/202 0/59
PPV2, PPV3
% (95% CI) 4.5 (1.2–11.1) 2.5 (0.1–13.2) 7.3 (1.5–19.9) 0.0 (0.0–37.0) >0.999
No./total 4/89 1/40 3/41 0/8
Biopsy rate
% (95% CI) 9.6 (7.8–12.0) 11.1 (8.6–15.8) 10.4 (7.8–14.7) 4.8 (2.5–9.5) 0.040
No./total 96/998 44/395 43/414 9/189
Noninitial examination
PPV1
% (95% CI) 1.4 (0.5–3.2) 0.8 (0.2–4.5) 1.4 (0.2–4.8) 2.2 (0.3–7.7) 0.563
No./total 5/360 1/122 2/147 2/91
PPV2, PPV3
% (95% CI) 11.9 (4.0–25.6) 6.7 (0.5–32.0) 14.3 (1.8–42.8) 15.4 (1.9–45.5) 0.574
No./total 5/42 1/15 2/14 2/13
Biopsy rate
% (95% CI) 2.3 (1.7–3.2) 3.4 (1.9–4.7) 2.1 (1.1–3.2) 1.8 (1.0–3.1) 0.033
No./total 51/2173 23/583 16/759 15/831
Overall= from ﬁrst to third year. Total examination= initial plus noninitial examination. P value for trends over 3 years using Mantel–Haenszel chi-square test. CI= conﬁdence interval, PPV= positive predictive value.
Kim et al. Medicine (2016) 95:44 Medicine
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Kim et al. Medicine (2016) 95:44 www.md-journal.com7radiologists was not performed. In our study, categories 3 to
4a rates were signiﬁcantly higher in less-experienced than
experienced radiologists, although there were no differences in
total cancer yields. In fact, the more important observation was
that the gap in the categories 3 to 4a rate between the 2 groups
decreased over 3 years, which supported the effectiveness of the
downgrade criteria not only for generally decreasing categories 3
to 4a but also for decreasing the performance gaps between less-
experienced and experienced radiologists.
Our total cancer yield of 2.5 cancers per 1000 examinationswas
similar to the resultsof theConnecticut studies (1.8–3.2 cancersper
1000 examinations), which may reﬂect the performance of
screening US performed on the general population who are at
average risk of breast cancer (i.e., women without known risk
factors of breast cancer other than dense breast).[6,7,11] The
characteristics of screeningUS-detected cancers havebeen reported
to be invasive (median, 91%, range, 50%–100%), node-negative
(median, 87.5%, range, 78%–100%), and less than 1.0cm in size
(range, 6.5–19mm),[4–6,8,9,11] consistent with our results.
In noninitial examinations (incidence screening), the cancer
detection rate, positive test rate, and biopsy rate were lower, and
the PPVswere higher compared to initial examinations (prevalence
screening) with statistical signiﬁcance for the positive test rate and
biopsy rate.[14] These results were consistent with our initial
hypothesis (refer to the study population in Section 2.1 for a more
detailed explanation) and the ACRIN 6666 trial results of
combined mammography plus US screening which showed that
cancer detection rates, biopsy rates, short-term follow-up rates
decreased, and PPVs increased in the incidence screening.
There were several limitations in our study. This study was
retrospectively conducted in a single institution, third-referral
center by breast radiologists. Generalization of the results may be
limited for other study populations, and for examinations
performed by technologist or less-experienced physicians.
Selection bias might have occurred owing to the exclusion of
women without follow-up US for at least 1 year. Due to the
retrospective nature of our study, we could not analyze from our
collected data whether the downgrade criteria was properly
applied per patient-level by each radiologist. More systematic
training programs and quality control programs using videos,
still images, or tests are needed to monitor the quality of each
radiologist’s classiﬁcation abilities with the downgrade criteria.
Further large-scale, multicenter, prospective studies are needed to
validate the effectiveness of the downgrade criteria.
In conclusion, the application of the downgrade criteria to
supplemental screening US for women with negative mammog-
raphy but dense breasts reduced BI-RADS categories 3 to 4a
without a loss of cancer detection.Acknowledgment
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